60 Degrees Pharmaceuticals, Inc. (SXTPW) company profile
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
About 60 Degrees Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes therapies to prevent and treat infectious conditions. Its primary commercial product is Arakoda, an approved tafenoquine regimen used for malaria prevention. The company also maintains development programs targeting fungal, viral, and vector-borne diseases. Its clinical pipeline explores additional regimens containing tafenoquine, alongside compounds such as celgosivir and botanical extracts derived from Australian chestnut trees. It provides treatments for individuals exposed to infectious illnesses and distributes therapies through commercial pharmaceutical distributors.
The company maintains its corporate headquarters in Washington, D.C. Beyond its primary operations in the United States, it manages an international presence through a majority-owned subsidiary located in Sydney, Australia. This subsidiary, 60P Australia Pty Ltd, oversees sub-licensing rights for products across multiple territories outside the United States.
Summary of the business section of 60 Degrees Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- 60 Degrees Pharmaceuticals, Inc.
- Founded
- 2022
- Headquarters
- Washington, DC
- Address
- 1025 Connecticut Avenue Nw, Suite 1000 20036
- Phone
- (202) 327-5422
- Website
- 60degreespharma.com
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, Las Vegas, Nevada
Stock & identifiers
- Ticker
- SXTPW
- Other tickers
- SXTP
- Exchange
- Nasdaq
- IPO date
- Jul 13, 2023
- Shares outstanding
- 4M, Aug 14, 2026
- Public float
- $3.34M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-4 reverse, Jan 20, 2026; 1-for-5 reverse, Feb 24, 2025; 1-for-12 reverse, Aug 12, 2024
- SEC CIK
- 1946563
- CUSIP
- 83006G112
- ISIN
- US83006G1123
- FIGI
- BBG01H0F52W2
- EIN
- 45-2406880
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Geoffrey S. Dow | President and CEO, Director | 35,250 |
| Kristen Landon | Chief Operating Officer | 4,540 |
| Tyrone Miller | CFO | 26,370 |
| Eric Francois | Director | – |
| Cheryl Xu | Director | 13,816 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Geoffrey Dow President and Chief Executive Officer (Principal Executive Officer) | $250.00K | – | $477.75K | $727.75K | +125% |
| Tyrone Miller Chief Financial Officer (Principal Financial and Accounting Officer) | $215.00K | – | $68.25K | $283.25K | -0% |
| Kristen Landon Chief Commercial Officer | $300.00K | $11.79K | – | $311.79K | -34% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 13, 2023
- Offer price
- $5.30
- Securities offered
- 1,415,095
- Gross proceeds
- $7.50M
- Exchange
- Nasdaq
- First trading day
- Jul 12, 2023
- First-day close
- $4.68-11.7%
- Lock-up ends (est.)
- Jan 8, 2024
“The initial public offering price of our Units is $5.30 per Unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025 , we had a total of three employees, all of whom are full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 23, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 28, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 15, 2023 | Late filing | Notification of late filing |
| Nov 3, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 13, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 14, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |